Overview
- Peptide (C)GDSPPGNGSGPRHIND corresponding to amino acid residues 366-381 of the human Nogo Receptor (Accession Q9BZR6). Extracellular.
- Mouse BV-2 microglia cells; human THP-1 monocytic leukemia cells (2.5 µg).
- Cell surface detection of Nogo Receptor in live intact mouse BV-2 microglia cells:___ Cells.
___ Cells + rabbit IgG isotype control-FITC.
___ Cells + Anti-Nogo Receptor (extracellular)-FITC Antibody (#ANT-008-F), (2.5 µg).
Neurite outgrowth inhibitor receptor 1 (NgR1, Nogo Receptor) is a glycosylphosphatidylinositol (GPI) transmembrane protein expressed on the surface of axons in the CNS. Its key binding domain is an extracellular leucine-rich repeat domain that interacts with Myelin-associated inhibitory factors (MAIFs) composed of MAG, Neurite outgrowth inhibitor (Nogo)-A, and OMgp1,2.
NgR1 binds to Neurite outgrowth inhibitor (Nogo) through a short hydrophilic loop between two hydrophobic domains. This binding activates intracellular molecular switches through the heteromerization with NgR1 co-receptors, p75NTR and LINGO-1.
This process facilitates neurite outgrowth dynamics; it also governs the plasticity of the CNS at the axo-dendritic and axo-glial levels3.
During CNS neurodegenerative disorders and in animal models of inflammatory demyelination, MAIFs, containing Nogo, accumulate and therefore there is an increased binding to their cognate receptor. This marks Nogo-NgR1 interaction as a potential target of new therapeutics for neurodegenerative diseases4.